
MUSTANG BIO, INC. — Investor Relations & Filings
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies. The company's primary focus is on translating medical breakthroughs into potential cures for difficult-to-treat cancers and rare genetic diseases. Its pipeline is centered on Chimeric Antigen Receptor (CAR) T-cell therapies, a form of immunotherapy. Mustang Bio's strategy involves in-licensing promising technologies from academic institutions and advancing them through clinical trials, supported by its in-house manufacturing capabilities to ensure the production and delivery of these advanced treatments.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - MUSTANG BIO, INC. (0001680048) (Filer) | 2026-05-05 | English | |
| 8-K - MUSTANG BIO, INC. (0001680048) (Filer) | 2026-04-17 | English | |
| Major Shareholding Notification 2026 | 2026-01-05 | English | |
| Director's Dealing 2026 | 2026-01-05 | English | |
| OWNERSHIP DOCUMENT | 2025-12-30 | English | |
| OWNERSHIP DOCUMENT | 2025-12-30 | English |
Browse filings by year
11 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
4 filings
| |||||
| 41519352 | 10-Q - MUSTANG BIO, INC. (0001680048) (Filer) | 2026-05-05 | English | ||
| 34661932 | 8-K - MUSTANG BIO, INC. (0001680048) (Filer) | 2026-04-17 | English | ||
| 12973079 | Major Shareholding Notification 2026 | 2026-01-05 | English | ||
| 12973078 | Director's Dealing 2026 | 2026-01-05 | English | ||
|
2025
11 filings
| |||||
| 12973080 | OWNERSHIP DOCUMENT | 2025-12-30 | English | ||
| 12973081 | OWNERSHIP DOCUMENT | 2025-12-30 | English | ||
| 12973082 | OWNERSHIP DOCUMENT | 2025-12-30 | English | ||
| 12973084 | 8-K | 2025-12-23 | English | ||
| 12973083 | DEF 14A | 2025-12-03 | English | ||
| 12973085 | 10-Q | 2025-11-07 | English | ||
| 12973086 | Major Shareholding Notification 2025 | 2025-10-01 | English | ||
| 12973089 | Director's Dealing 2025 | 2025-10-01 | English | ||
| 12973087 | 424B5 | 2025-09-05 | English | ||
| 12973088 | Major Shareholding Notification 2025 | 2025-08-12 | English | ||
| 12973090 | 10-Q | 2025-08-08 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Ajanta Pharma Ltd.
Specialty pharmaceutical firm focused on complex generics a…
|
AJANTPHARM | IN | Manufacturing |
|
Akari Therapeutics Plc
Develops next-gen antibody-drug conjugates using proprietar…
|
AKTX | US | Manufacturing |
|
Akebia Therapeutics, Inc.
A biopharmaceutical company that develops and commercialize…
|
AKBA | US | Manufacturing |
|
Akeso, Inc.
Global commercial-stage biopharma developing innovative ant…
|
9926 | KY | Manufacturing |
|
Aktis Oncology, Inc.
A clinical-stage biotech developing targeted alpha radiopha…
|
AKTS | US | Manufacturing |
|
Akums Drugs and Pharmaceuticals Limited
CDMO providing end-to-end pharmaceutical manufacturing and …
|
AKUMS | IN | Manufacturing |
|
Albert David Ltd.
Produces pharmaceutical formulations, infusions, and specia…
|
ALBERTDAVD | IN | Manufacturing |
|
Aldeyra Therapeutics, Inc.
Develops medications for immune-mediated ocular and systemi…
|
ALDX | US | Manufacturing |
|
Aleafia Health Inc.
Vertically integrated cannabis company with cultivation, pr…
|
AH | CA | Manufacturing |
|
Alector, Inc.
Clinical-stage biotech using immuno-neurology to treat neur…
|
ALEC | US | Manufacturing |
MUSTANG BIO, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35167/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35167 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35167 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35167 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35167}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for MUSTANG BIO, INC. (id: 35167)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.